In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
All content for WTR Healthcare Happenings is the property of Joe Brunetto and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries
WTR Healthcare Happenings
16 minutes
3 weeks ago
Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries
In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (TSXV: NRX | OTCQB: NRXBF), and Yoram Drucker, Founder, VP of Business Development, and Active Chairman, join host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, along with WTR Senior Equity Research Analyst Robert Sassoon. The conversation explores NurExone’s groundbreaking exosome-based ExoTherapy platform and its lead candidate ExoPTEN, designed to regenerate damaged neurons followin...
WTR Healthcare Happenings
In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.
